
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:1335</ns1:identifier>
    <ns1:title language="sr">Prediktivna vrednost evociranih potencijala na dugotrajni ishod multiple skleroze</ns1:title>
    <ns2:alt_title language="sr">Predictive value of evoked potentials on the long-term outcome of multiple sclerosis : doctoral dissertation</ns2:alt_title>
    <ns1:language>sr</ns1:language>
    <ns1:description language="sr">Uvod: Cilj je bio da ispitamo prediktivnu vrednost evociranih potencijala (EP) na dostizanje povoljnog ishoda dugogodišnjeg lečenja imunomodulatornom terapijom obolelih od relapsno-remitentne multiple skleroze (RRMS), da procenimo značaj EP kao pokazatelja kognitivnog oštećenja, i uticaj depresije i zamora na EP i ishod
lečenja.
Metodologija: U retro- i prospektivnom istraživanju oboleli su praćeni tokom 2, 5
ili 10 godina. Na početku praćenja su rađeni vizuelni evocirani potencijali (VEP) i
kognitivni EP (ERP), takođe i nakon dugogodišnjeg praćenja. Dobijeni su podaci o
optičkom neuritisu (ON), procenjeni stepen onesposobljenosti, kognitivne funkcije,
stepen depresivnosti i zamora, rađena magnetna rezonanca (MR) endokranijuma.
Povoljan ishod lečenja predstavlja dostizanje NEDA-3 (No Evidence of Disease
Activity).
Rezultati: Učestvovalo je 112 sobolelih od RRMS i 32 zdrave kontrole. NEDA-3 je
dostiglo 19 (22,9%), a nije dostiglo 64 (77,1%) lečenih od RRMS. Nalaz EP skora
(r=0,008, OR=0,344 (0,156–0,757)) i latence (r=0,042, OR=0,966 (0,934–0,999)) na
početku bolesti su prediktivni faktori na dostizanje NEDA-3. Depresija utiče na
kognitivno oštećenje (r=0,047, OR=1,077 (1,001–1,159)) i povećanje onesposobljenosti
(r=0,002, OR=1,143 (1,051–1,243)). Depresija i zamor negativno utiču na kognitivne
funkcije, a ne utiču na amplitude i latence ERP. Reakciono vreme pozitivno
korelira sa depresijom (r=0,246, p=0,01) i zamorom (r=0,281, p=0,01).
Zaključak: Uredan VEP na početku bolesti uvećava šansu za dostizanje NEDA-3 oko 6
puta. Depresija utiče na povećanje onesposobljenosti i kognitivno oštećenje.
Depresija i zamor negativno utiču na kognitivne funkcije, a ne utiču na amplitudu i
latencu ERP. ERP ne mogu učestvovati u proceni kognitivnog oštećenja obolelih od
RRMS. </ns1:description>
    <ns1:description language="en">Objective: The study examined predictive value of evoked potentials (EP) to achieve a outcome of long-term treatment of patients with relapsing-remitting multiple sclerosis (RRMS) with first-line immunomodulatory therapy, to assess EP as an indicator of cognitive impairment, and impact of depression and fatigue on EP and the outcome of treatment.
Method: In retrospective and prospective study patients were followed for 2, 5 or
10years. At the diagnosis visual evoked potentials (VEP) and event-related potentials (ERP) were done, also after follow-up period. Each patient was assigned a degree of disability – EDSS (Expanded Disability Status Scale), cognitive functions, degree of depression and
fatigue, MRI of the endocranium. Favourable outcome is achieving NEDA-3 (No Evidence of
Disease Activity).
Results: A total of 112 patients with RRMS and 32 healthy controls participated.
NEDA-3 reached 19 (22,9%) and did not 64 (77,1%) treated patients. We found that the VEP
score (р=0,008, OR=0,344 (0,156–0,757)) and latency (r=0,042, OR=0,966 (0,934–0,999)) at
diagnosis were predictive factors to achieve NEDA-3. Depression affects cognitive
impairment (r=0,047, OR=1,077 (1,001-1,159)) and increases future disability (r=0,002,
OR=1,143 (1,051-1,243)). Depression and fatigue negatively affected cognitive functions, and
did not affect the ERP. Reaction time (RT) positively correlated with depression (r=0,246,
p=0,01) and fatigue (r =0,281, p=0,01).
Conclusions: Normal EP findings at diagnosis are 6 times more likely to achieve
NEDA. Depression affects disability and cognitive impairment. Depression and fatigue have a negative impact on cognitive functions, and have no effect on ERP. Amplitude and latency cannot participate in risk assessment for the cognitive impairment in patients with RRMS. </ns1:description>
    <ns1:description language="sr"></ns1:description>
    <ns2:identifiers>
      <ns2:identifier>ID=35222025 ; D=3410</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552101</ns2:resource>
      <ns2:identifier>8022</ns2:identifier>
    </ns2:identifiers>
    <ns2:identifiers>
      <ns2:resource>91552100</ns2:resource>
      <ns2:identifier>35222025</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2021-03-29T16:17:28.053Z</ns1:upload_date>
    <ns1:status>45</ns1:status>
    <ns2:peer_reviewed>no</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Snežana, 1985-, 61397513</ns3:firstname>
        <ns3:lastname>Simović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="1">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>mentor</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Svetlana, 1965-, 6278247</ns3:firstname>
        <ns3:lastname>Miletić Drakulić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="2">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>predsednik komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Tihomir, 1966-, 13762919</ns3:firstname>
        <ns3:lastname>Ilić</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="3">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Ivan, 1985-, 14277991</ns3:firstname>
        <ns3:lastname>Srejović</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
    <ns1:contribute seq="4">
      <ns1:role>63</ns1:role>
      <ns1:ext_role>član komisije</ns1:ext_role>
      <ns1:entity seq="0">
        <ns3:firstname> Milica, 1980-, 24912231</ns3:firstname>
        <ns3:lastname>Borovčanin</ns3:lastname>
      </ns1:entity>
      <ns1:date>2020</ns1:date>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>68 листова</ns1:format>
    <ns1:size>1594516</ns1:size>
    <ns1:location>http://phaidrabg.bg.ac.rs/o:1335</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>4</ns1:license>
  </ns1:rights>
  <ns1:annotation>
    <ns6:annotations>
      <ns6:date>2021-03-29T16:17:28.320Z</ns6:date>
    </ns6:annotations>
  </ns1:annotation>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
    <ns7:keyword language="sr" seq="1">multipla skleroza, evocirani potencijali, depresija, zamor,kognitivno oštećenje, optički neuritis, NEDA. </ns7:keyword>
    <ns7:keyword language="sr" seq="1">multiple sclerosis, evoked potentials, depression, fatigue, cognitiveimpairment, optic neuritis, NEDA.</ns7:keyword>
    <ns7:keyword language="sr" seq="1">616.832-004(043.3)</ns7:keyword>
    <ns7:keyword language="sr" seq="1">Multipla skleroza - Imunomodulatori - Lečenje</ns7:keyword>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1738</ns8:hoschtyp>
    <ns8:orgassignment>
      <ns8:faculty>34A05</ns8:faculty>
    </ns8:orgassignment>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:releaseyear>2020</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
